What if one of America’s largest health programs couldn’t hold up to the scrutiny of scientific standards used for a mere pharmaceutical drug? That’s the startling claim in a recent critique questioning the efficacy of Medicaid.
At a Glance
- Michael F. Cannon critiques Medicaid’s lack of rigorous evidence.
- The Oregon Health Insurance Experiment found no significant health outcome improvements.
- Critics argue for the validity of broader evidence beyond RCTs.
- The debate highlights the ideological divide over government healthcare.
Medicaid Under the Microscope
Michael F. Cannon, a leading libertarian health policy scholar, has once again stirred the waters of healthcare reform with his latest critique featured in the Wall Street Journal. He argues that Medicaid, a colossal health program, lacks the randomized controlled trial (RCT) evidence necessary to meet the federal government’s own standards for efficacy and safety. If Medicaid were a pharmaceutical product, it might not pass the FDA’s rigorous testing requirements. This bold claim pushes the conversation about how we evaluate massive public health interventions.
What Mr. Cannon is really saying is the for $45T spent since 1965, Medicare and Medicaid have successfully bloated the Health Care industry…improving Americans health…not so much!!!
Medicare and Medicaid Fail a Basic Scientific Test by @mfcannon https://t.co/HcD08rhJXU via…
— Robert Wagner (@RobertW37463604) July 22, 2025
The Oregon Health Insurance Experiment (OHIE), a rare instance of RCT conducted on Medicaid, did not find statistically significant improvements in mortality or other physical health outcomes. Cannon uses this as a basis to call for more extensive RCTs to settle uncertainties about Medicaid’s true health impacts. However, critics, including respected economists and journalists, argue that Cannon’s focus on mortality outcomes is too narrow and overlooks the broader benefits of Medicaid.
The Clash of Ideologies
The disagreement isn’t just about numbers and graphs; it’s about the role of government and the standards we set for publicly funded programs. Critics, including MIT economist Amy Finkelstein, assert that while RCTs are valuable, they are not the only valid form of evidence. Observational studies, they argue, provide significant insights, especially when conducting large-scale RCTs is impractical or unethical.
This debate takes place against a backdrop of political battles over healthcare reform and Medicaid expansion. Cannon and his coauthor, Brian Blase, continue to demand higher evidentiary standards for government interventions, echoing a broader libertarian and conservative sentiment. Meanwhile, their opponents emphasize the practical benefits of Medicaid, especially in states that expanded it under the Affordable Care Act.
Implications for Public Policy
The implications of this debate are profound. In the short term, it shapes the discourse around Medicaid expansion, funding, and reform. Policymakers and the public are left questioning the scientific rigor behind major health programs that affect millions of Americans. In the long run, it could redefine how health policies and interventions are evaluated, potentially pushing for a greater demand for RCTs.
Medicaid is a nearly $1 trillion program impacting over 70 million Americans. Changes in how its effectiveness is evaluated could have substantial fiscal and social consequences. The debate reflects broader ideological divides over the government’s role in healthcare, a topic that resonates deeply with conservative values of limited government and fiscal responsibility.
